Redhill Biopharma Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Redhill Biopharma Stock Summary

Redhill Biopharma competes with Organogenesis Holdings, Lifecore Biomedical, Collegium Pharmaceutical, Aquestive Therapeutics, and Evoke Pharma. RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel. Redhill Biophrma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 201 people.

Redhill Biopharma Key Financial Ratios

Redhill Biopharma Key Balance Sheet Accounts

Redhill Biopharma Key Income Statement Accounts

Redhill Biopharma Key Cash Accounts

Redhill Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Redhill Biopharma's current stock value. Our valuation model uses many indicators to compare Redhill Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Redhill Biopharma competition to find correlations between indicators driving Redhill Biopharma's intrinsic value. More Info.Redhill Biopharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Redhill Biopharma's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Redhill Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Redhill Biopharma Systematic Risk

Today, most investors in Redhill Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Redhill Biopharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Redhill Biopharma growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Redhill Biopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Redhill Biopharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Redhill Biopharma based on widely used predictive technical indicators. In general, we focus on analyzing Redhill Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Redhill Biopharma's daily price indicators and compare them against related drivers.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.